1446358-48-0

Basic information

• Product Name: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole
• Synonyms: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole
• CAS NO: 1446358-48-0
• Molecular Weight: 373.749
• Mol File: 1446358-48-0.mol

Chemical Properties

• CAS DataBase Reference: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(1446358-48-0)
• EPA Substance Registry System: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(1446358-48-0)

Safety Data

• Hazardous Substances Data: 1446358-48-0(Hazardous Substances Data)

Upstream product

• 1446353-53-2 C₁₄H₁₀FN₃O₃ 
• 1446353-66-7 C₁₄H₉FN₄O 
• 1354044-05-5 1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazole-3-carboximidamide hydrochloride 
• 1354044-23-7 1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazole-3-carboximidamide 
• 1354041-91-0 5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)-pyrimidin-4-ol 
• 88511-37-9 1-(isoxazol-3-yl)ethan-1-one 
• 1579999-84-0 C₉H₈NO₅^(1-)*Li⁽¹⁺⁾ 
• 1446359-43-8 3-(3-(4,6-dichloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1446359-44-9 3-(3-(4-chloro-5-fluoro-6-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1446358-49-1 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1330044-11-5 5-fluoro-4-methoxy-2-[(trimethylsilyl)ethynyl]pyrimidine 
• 1330044-12-6 2-ethynyl-5-fluoro-4-methoxypyrimidine 

Downstream Products

• 1446358-49-1 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1446358-50-4 C₁₇H₁₃F₂N₇O 
• 1446359-60-9 C₁₉H₁₂F₂N₆O 
• 1446359-52-9 C₁₈H₁₀F₂N₆O 
• 1446359-91-6 C₂₄H₂₀F₂N₆O₃ 

Relevant articles and documents

Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator

Soluble guanylate cyclase (sGC) is a clinically validated therapeutic target in the treatment of pulmonary hypertension. Modulators of sGC have the potential to treat diseases that are affected by dysregulation of the NO-sGC-cGMP signal transduction pathw

NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS

The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulat

SOLID DISPERSIONS COMPRISING A SGC STIMULATOR

The present invention relates to solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol (Compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositions and pharmaceutical oral dosage unit forms comprising them, and their uses thereof.

PYRAZOLE DERIVATIVES AS SGC STIMULATORS

There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans

In recent years, soluble guanylate cyclase (sGC, EC 4.6.1.2) has emerged as an attractive therapeutic target for treating cardiovascular diseases and diseases associated with fibrosis and end-organ failure. Herein, we describe our design and synthesis of

SGC STIMULATORS

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, Formula (I) wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC

sGC STIMULATORS

The present patent application discloses at least the compounds according to Formula (Ia) and Formula (Ib) shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, JB, n, J, RC1, RC2, Z1, Z2, W, X, Y1, Y2, JF and R9 are as defined herein.

SGC STIMULATORS

Compounds of Formulae (I') and (I) are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS

2-Benzyl, 3 - (pyrimidin- 2 -YL) substituted pyrazoles are described. They are useful as stimulators of sGC, particularly NO - independent, heme - dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.